Staidson (Beijing) BioPharmaceuticals Co., Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was CNY 123.34 million compared to CNY 115.46 million a year ago. Revenue was CNY 123.34 million compared to CNY 115.46 million a year ago. Net loss was CNY 24.41 million compared to CNY 19.91 million a year ago. Basic loss per share from continuing operations was CNY 0.05 compared to CNY 0.04 a year ago. Diluted loss per share from continuing operations was CNY 0.05 compared to CNY 0.04 a year ago.